4月13日 -
** Kymera Therapeutics KYMR.O股价盘前上涨2%至86.50美元
** 生物技术公司称，美国食品和药物管理局授予KT-621 "快速通道 "资格，KT-621是一种治疗中度至重度嗜酸性粒细胞性哮喘的实验性日服一次药片，这是一种与气道高水平炎症相关、难以治疗的哮喘。
** 补充说，KT-621 的靶点是驱动炎症的免疫通路，旨在改善对现有吸入剂或注射剂反应不佳的患者的症状控制。
** 正在进行哮喘的中期试验，预计将于 2027 年底得出结果，另外还在进行特应性皮炎（一种慢性皮肤病）的中期试验，预计将于 2027 年中期得出数据 - KYMR
** "快速通道 "资格旨在加快开发和审查医疗需求未得到满足的严重疾病的治疗方法。
** 截至上一交易日收盘，股价年累计上涨约 9%
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.